Agios Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
Agios Pharmaceuticals Stock Forecast and Price Target
According to four esteemed experts, the average price target for Agios Pharmaceuticals to reach this year is $43.50, with a potential upside of approximately 41.23%. This prediction is based on a high estimate of $49.00 and a low estimate of $29.00. If you're not interested in AGIO stock, you may be interested in its competitors.
41.23% Upside
Agios Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Agios Pharmaceuticals's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $33.41, which would mean an increase of 100.00%. Over the next seven years, experts predict that Agios Pharmaceuticals's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ABBV Stock Forecast | AbbVie | Outperform |
9
|
$179.63 | Buy/Sell | $178.42 | 0.21% |
AMGN Stock Forecast | Amgen | Outperform |
4
|
$275.36 | Buy/Sell | $303.65 | 14.40% |
GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$75.32 | Buy/Sell | $87.82 | 10.20% |
ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.07 | Buy/Sell | $299.62 | 29.09% |
Agios Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last year, Agios Pharmaceuticals's Revenue has grown by 88.34%, rising from $14.24M to $26.82M. For next year, analysts predict Revenue of $51.58M, which would mean an increase of 92.32%. Over the next seven years, experts predict that Agios Pharmaceuticals's Revenue will grow at a rate of 4595.64%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$86.00 | Buy/Sell | $111.56 | 26.40% |
INCY Stock Forecast | Incyte | Outperform |
9
|
$60.79 | Buy/Sell | $77.05 | 26.99% |
ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$89.47 | Buy/Sell | $85.71 | 11.77% |
IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$15.10 | Buy/Sell | $20.42 | 68.87% |
ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$24.13 | Buy/Sell | $33.78 | 32.62% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$12.13 | Buy/Sell | $17.90 | 64.88% |
CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
CBAY Stock Forecast | CymaBay Therapeutics | Hold |
8
|
$32.44 | Buy/Sell | $27.73 | 0.18% |
Agios Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
Agios Pharmaceuticals's EBITDA has seen impressive growth In the last three years, rising from $-326.13M to $-384.86M – a growth of 18.01%. In the following year, 3 experts forecast that Agios Pharmaceuticals's EBITDA will decrease by 13.25%, to $-333.87M. For the next seven years, the forecast is for EBITDA to grow by 19.67%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$29.40 | Buy/Sell | $52.00 | 87.07% |
VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$63.44 | Buy/Sell | $34.00 | 73.39% |
DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
Agios Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Agios Pharmaceuticals's EBIT has grown by 16.54%, rising from $-335.92M to $-391.49M. 7 analysts predict Agios Pharmaceuticals's EBIT will decrease by 8.16% in the next year, reaching $-359.53M. By 2030, professionals predict that Agios Pharmaceuticals's EBIT will decrease by 203.94%, to $406.92M.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$46.54 | Buy/Sell | $63.29 | 65.45% |
VCEL Stock Forecast | Vericel | Buy |
8
|
$44.59 | Buy/Sell | $42.58 | 18.86% |
ARDX Stock Forecast | Ardelyx | Buy |
11
|
$8.49 | Buy/Sell | $9.94 | 56.07% |
Agios Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Agios Pharmaceuticals's EPS has grown by 100.00%, rising from $-4.74 to $0.00. For next year, analysts predict EPS of $-5.07, which would mean an increase of 100.00%. Over the next seven years, experts predict that Agios Pharmaceuticals's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$12.97 | Buy/Sell | $25.00 | 88.90% |
XNCR Stock Forecast | Xencor | Outperform |
6
|
$23.13 | Buy/Sell | $37.91 | 47.00% |
SAGE Stock Forecast | Sage Therapeutics | Hold |
6
|
$21.18 | Buy/Sell | $25.28 | 18.04% |